Quantcast

Aeterna Zentaris to Make Presentations on Novel Anticancer Compounds at Upcoming Bio Partnering North America in Vancouver and RBC Capital Markets Healthcare Conference in New York

February 22, 2011

QUÓ°BEC CITY, Feb. 22 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ) (the “Company”) today announced that its Vice President,
Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D.,
will make a presentation on two of the Company’s novel anticancer
compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on
Monday, February 28, 2011, at 4 p.m. (Pacific Time) in the West Meeting
Room 218, of the Vancouver Convention Center in Vancouver, Canada.

AEZS-108, the LHRH targeted cytotoxic peptide conjugate composed of a
peptide carrier and a cytotoxic agent (doxorubicin), has successfully
completed a Phase 2 program in advanced ovarian and advanced
endometrial cancer. This compound is also currently in Phase 1/2 trials
in refractory prostate cancer and bladder cancer. AEZS-129, an
orally-active PI3K inhibitor compound, is in preclinical development in
oncology.

Furthermore, Company President and CEO, Juergen Engel, Ph.D., will take
part in a panel discussion on novel cancer treatments at the upcoming
RBC Capital Markets Healthcare Conference. The panel discussion
entitled, “Cancer Treatments: Under the Radar Unique Late-Stage Opportunities“, will take place on Wednesday, March 2, 2011, at 9 a.m. (Eastern Time)
in the Holmes I Room of the New York Palace Hotel, in New York City.

A live audio webcast of the panel discussion will be available on
Aeterna Zentaris’ website at www.aezsinc.com, in the Newsroom section. A replay of the webcast will also be
available on the Company’s website for a period of 90 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company
currently investigating potential treatments for various cancers
including colorectal, ovarian, endometrial cancer and multiple myeloma.
The Company’s innovative approach of “personalized medicine” means
tailoring treatments to a patient’s specific condition and to unmet
medical needs. Aeterna Zentaris’ deep pipeline is drawn from its
proprietary discovery unit providing the Company with constant and
long-term access to state-of-the-art therapeutic options. For more
information please visit www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.


Source: newswire



comments powered by Disqus